TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Dexmedetomidine Premedication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Surgery:The laryngoscope vocal polyp excision~* Aged 18 to 60 years old~* Body mass index (BMI) \< 30 kg/m2~* American society of Anesthesiologist (ASA) I -II~Exclusion Criteria:~* The investigator refused to participate~* Known allergy or hypersensitive reaction to dexmedetomidine or anesthetic~* With previous history of heart disease~* Pregnant women; no reliable contraceptive measures in postmenopausal women~* Preoperative heart rate less than 45bpm; Ⅱ or Ⅲ degree atrioventricular block; ischemic heart disease~* Taking antihypertensive drugs such as methyldopa, clonidine and other α2 receptor agonist~* Asthma~* Sleep apnea syndrome~* Liver and kidney dysfunction~* Known to suffer from mental illness~* Long-term use of sedatives and analgesics in patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- dexmedetomidine (Type: ACTIVE_COMPARATOR): intranasal dexmedetomidine
- placebo (Type: PLACEBO_COMPARATOR): intranasal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DPNB for Prevention of CRDB

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent signed~* Male adult patient, aged 18\~50 years old, ASA I\~III~* Surgery under general anesthesia~Exclusion Criteria:~* Bladder dysfunction, such as overactive bladder~* A history of bladder outflow obstruction~* Prostate disease, such as benign prostate hyperplasia, etc.~* Disturbance of central nervous system

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- DPNB (Type: EXPERIMENTAL): Patients receive DPNB 30min before extubation at the end of operation.
- Tramadol (Type: ACTIVE_COMPARATOR): Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute myeloid leukemia diagnosed by WHO criteria with one of the following:~   1. Primary refractory disease following \>= 1 rounds of induction chemotherapy~  2. First relapse or higher~2. Age between 18 and 70 years of age~3. Adequate organ function defined as Creatinine \<= 1.5 x institutional ULN; AST, ALT, total bilirubin \<= 2 x ULN; Left ventricular ejection fraction of \>= 40% by MUGA scan~4. Women of childbearing potential and sexually active males must be willing and able to use effective contraception while on study~5. Able to provide signed informed consent prior to registration on study~Exclusion Criteria:~1. Acute promyelocytic leukemia (AML with t(15;17)(q22;q11) and variants)~2. Peripheral blood blast count \> 20 x 103 /mm3~3. Active CNS involvement with leukemia~4. Previous treatment with MEC or other regimen containing both mitoxantrone and etoposide~5. Pregnant or nursing~6. Receiving any other investigational agent~7. Colony stimulating factors filgrastim, pegfilgrastim or sargramostim within 2 weeks of study~8. Less than 2 weeks from the completion of any previous cytotoxic chemotherapy~9. Severe concurrent illness that would limit compliance with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Phase I Dose Escalation (Type: EXPERIMENTAL): * AMD3100 SQ on days 0-5~* Mitoxantrone on days 1-5~* Etoposide on days 1-5~* Cytarabine on days 1-5~Dose Level 1 AMD3100 dose = 80 mcg/kg/d~Dose Level 2 AMD3100 dose = 160 mcg/kg/d
- Phase II Dose Treatment (Type: EXPERIMENTAL): * AMD 3100 SQ on days 0-5~* Mitoxantrone on days 1-5~* Etoposide on days 1-5~* Cytarabine on days 1-5~Dose Level 3 AMD3100 dose=240 mcg/kg/d (this was the Phase II dose)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Moxibustion for Primary Dysmenorrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Guidelines of Primary dysmenorrhea clinical by the Society of Obstetricians and Gynaecologists of Canada~* Menstrual cycle is regular (28±7) days~* Syndrome differentiation of Traditional Chinese Medicine: Congealing cold-damp and Qi-stagnation and blood stasis~* Mean value of ≥40mm during last 3 months~* Informed consent form must be signed by patient or lineal relative~Exclusion Criteria:~* Patients with secondary dysmenorrhea, which is caused by endometriosis, pelvic inflammation, myoma of uterus and so on~* Patients who are unconscious and psychotic~* Patients with serious primary illness or diseases of cardiovascular, liver, renal, gastrointestinal, hematological systems and so on~* Patients take prostaglandin synthetase inhibitors (PGSI) 2 weeks before inclusion~* Pregnant women or women in lactation

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Moxibustion treatment group (Type: EXPERIMENTAL): Apply traditional acupuncture to prevent the dysmenorrhea according to traditional Chinese medicine theory
- Medicine control group (Type: ACTIVE_COMPARATOR): Ibuprofen Sustained Release Capsules will be penetrated for dysmenorrhea

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Regarding the Clinical Efficacy of Synatura® in Patients With Chronic Bronchitis Type COPD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Post bronchodilator FEV1/FVC \< 0.7~2. Smoking history of ≥10 packs per year~3. 40 to \<75 years of age~4. Patients with symptoms of chronic bronchitis (in case they have symptoms of cough or sputum over 3 months)~Exclusion Criteria:~1. Patients with acute exacerbation~2. Patients with pneumonia~3. Patients with active tuberculosis~4. Pregnant women~5. Breast-feeding women~6. Patients with fructose intolerance

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Synatura® 15 mL (Type: EXPERIMENTAL): Synatura syrup single arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PF-06651600 for the Treatment of Alopecia Areata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of alopecia areata with no other cause of hair loss~* ≥50% hair loss of the scalp, including alopecia totalis and alopecia universalis, without evidence of terminal hair regrowth within 6 months~* Current episode of hair loss ≤10 years~Exclusion Criteria:~* Other types of alopecia or other diseases that can cause hair loss~* Other scalp diseases that could interfere with assessment of hair loss/regrowth~* Subjects with shaved heads must not enter the study until hair has grown back \& is considered stable by the investigator~* Any previous use of any Janus kinase (JAK) inhibitor

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence A (Type: EXPERIMENTAL): Induction dose given once daily (QD) for 4 weeks followed by maintenance dose #1 given QD for 44 weeks
- Sequence B (Type: EXPERIMENTAL): Induction dose given QD for 4 weeks followed by maintenance dose #2 given QD for 44 weeks
- Sequence C (Type: EXPERIMENTAL): Maintenance dose #1 given QD for 48 weeks
- Sequence D (Type: EXPERIMENTAL): Maintenance dose #2 given QD for 48 weeks
- Sequence E (Type: EXPERIMENTAL): Maintenance dose #3 given QD for 48 weeks
- Sequence F (Type: EXPERIMENTAL): Placebo given QD for 24 weeks followed by induction dose given QD for 4 weeks then maintenance dose #1 given QD for 20 weeks
- Sequence G (Type: EXPERIMENTAL): Placebo given QD for 24 weeks followed by maintenance dose #1 given QD for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 and \< 80~2. Type I or Type II Diabetes Mellitus~3. Stable ACE or ARB therapy for 4 weeks prior to study enrollment~4. Urinary protein \> 3000 mg/24 hrs~5. Patients with more than one protein lowering agent (e.g. ACE or ARB, or MR antagonist or Tekturna require two consecutive 24 hour urinary protein of 2000 mg/24 hrs.~Exclusion Criteria:~1. Age \<18 or \>80~2. HgbA1c \> 9.0% or 11% if using the (DCCT / NGSP) method.~3. eGFR \< 20 mls/min by MDRD formula or eGFR by (Cockoff-Gault 20 mls/min)~4. Dilated cardiomyopathy with known EF \< 40%~5. Pregnant or nursing mothers~6. Patients with an admission for diabetic ketoacidosis, or non-ketotic hyperosmolar coma within 6 months of study enrollment.~7. Patients with known mixed glomerulonephritis and diabetic glomerulopathy~8. Patients within 3 mths of operative procedures or chronic non-healing wounds~9. Patients with glucocorticoid-induced diabetes mellitus~10. Patients with known sensitivity to porcine protein products~11. Patients with bleeding gastric or duodenal ulcers requiring hospitalization six months prior to study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ACTH-16 units (Type: ACTIVE_COMPARATOR): Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
- ACTH-32 units (Type: ACTIVE_COMPARATOR): Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV negative person, who was assigned male or female at birth, who reports sex with another man in the last year and is in good general health~2. Aged 18-59 years~3. Not currently taking PrEP and no plans to initiate during study~4. Not currently taking PEP~5. Not currently taking doxycycline or other tetracycline-derived antibiotics and no plans to initiate during the study~6. Willing to use condoms consistently for the duration of the study~7. Able to provide informed consent in English~8. No plans for relocation in the next 4 months~9. Willing to undergo peripheral blood, urine, rectal or vaginal secretion collection, and a rectal or vaginal and cervical biopsy procedure~10. Willing to use study products as directed~11. Hepatitis B surface antigen (HBsAg) negative (screening lab test)~12. Creatinine clearance \>60 ml/min~Exclusion Criteria:~1. Currently infected with hepatitis virus and/ or has liver disease~2. Current or chronic history of kidney disease or creatinine clearance (CrCl)\<60 ml/min~3. Continued need for, or use during the 90 days prior to enrollment, of the following medications:~   1. Systemic immunomodulatory agents~  2. Supraphysiologic doses of steroids (short course steroids less than 7 days duration, allowable at the discretion of the investigators)~  3. Chemotherapy or radiation for treatment of malignancy~  4. Experimental medications, vaccines, or biologicals~4. Intent to use HIV antiretroviral pre/post-exposure prophylaxis (PrEP or PEP) during the study, outside of the study procedures~5. Intent to use doxycycline or other tetracycline-derived antibiotics during the course of the study, outside of the study procedures~6. Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study requirements~7. Not pregnant and no plans on getting pregnant throughout the duration of the study~8. Known allergic reaction to study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Doxycycline and Biktarvy (Type: EXPERIMENTAL): Participants will take both study drugs simultaneously at home approximately 1 hour before Visit 2 and will be instructed to take a timestamped photograph or videotape of themselves taking the dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women who are 60 to 90 years of age may be eligible to participate~* Bone mineral density (BMD) T-Score at hip or spine must be less than -2.5~Exclusion Criteria:~* BMD T-Score at the hip or the spine of less than -4.0~* Patients with any severe or more than two moderate vertebral fractures on spinal x-ray at entry

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered subcutaneously once every 6 months for 3 years.
- Denosumab 60 mg Q6M (Type: EXPERIMENTAL): Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children with Bipolar Disorder~* Must be able to swallow tablets~Exclusion Criteria:~* Children with general medical condition such as head injury, epilepsy, endocrine disorders~* Those who are on mood altering medications such as steroids, and those diagnosed with mental retardation are excluded to avoid confounding and contributing factors to mood swings.~* If we discover during the interview that the parent and/or child does not understand the consent/assent procedures, we will exclude them.~We expect only a small number of children to be excluded from the study due to exclusionary criteria. Selection of the subjects is not based on sex, race, or ethnic group.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Risperidone (Type: ACTIVE_COMPARATOR): Risperidone is an antimanic medication and is a second generation antipsychotic
- Divalproex sodium (Type: ACTIVE_COMPARATOR): Divalproex sodium is an antiepileptic medication and is a mood stabilizer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic pulmonary fibrosis for \>3 months \<5 years~* High resolution CT scan of chest consistent with IPF within the previous 12 months~* FVC \> 40% and \< 90% predicted, TLC \>40% \<80%, DLCo \>30% \<90%~* Chronic Cough - cough \>8 weeks~* Age \>50~* Non-child bearing potential~Exclusion Criteria:~* Pregnant or lactating women~* Women of child bearing potential~* Known etiology of lung fibrosis other than IPF~* Significant respiratory toxin exposure~* Collagen Vascular Disease~* Use of narcotic anti-cough agent in last week~* significant peripheral vascular disease or neuropathy~* history of seizures~* poorly controlled diabetes~* allergy to thalidomide

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental: Thalidomide, then placebo (Type: EXPERIMENTAL): Participants first received Thalidomide tablet for 12 weeks. After a washout period of two weeks, they then received placebo tablet for 12 weeks.
- Experimental: Placebo, then Thalidomide (Type: EXPERIMENTAL): Participants first received Placebo tablet for 12 weeks. After a washout period of two weeks, they then received Thalidomide tablet for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Are male or female patients, 13 to 17 years of age~* Patients must have a diagnosis of schizophrenia per DSM-IV-TR.~* Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment.~* Both the patient and the patient's parent/authorized legal representative must understand the nature of the study and must sign a document granting consent.~* Patients must be capable of swallowing study medication whole (without crushing, dissolving, etc.)~Exclusion Criteria:~* Female patients who are either pregnant or nursing.~* Patients with acute or unstable medical conditions.~* Patients who have been judged clinically to be at serious suicidal risks.~* Patients who have previously not responded to an adequate dose and/or duration of olanzapine treatment.~* Patients who currently have delusional disorder, psychotic disorder NOS, schizophreniform, schizoaffective disorder, bipolar disorder, attention deficit/hyperactivity disorder or major depressive disorder.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older, of either gender, and of any race~* has never been treated with cisplatin and is to receive the first course of cisplatin-based chemotherapy (≥60 mg/m2)~* Karnofsky performance score of ≥60~* Predicted life expectancy of ≥4 months~* Adequate bone marrow, kidney, and liver function~Exclusion Criteria:~* Contraindication to cisplatin, granisetron, or dexamethasone~* Is pregnant or breast feeding~* Has previously received cisplatin or subject is planning to receive multiple days of cisplatin in a single cycle~* Has taken the following agents within the last 48 hours 5-HT3 antagonists,Phenothiazines,Benzamides,Domperidone,Cannabinoids,NK1 antagonist, Benzodiazepines~* Scheduled to receive any other chemotherapeutic agent with an emetogenicity level of 4 or above (Hesketh Scale) from Day 2 through Day 6, except on Day 1.~* Scheduled to receive any radiation therapy to the abdomen or pelvis from Day -5 through Day 6~* Has received systemic corticosteroids or sedative antihistamines within 72 hours of Day 1 of the study except as premedication for chemotherapy (e.g., taxanes, pemetrexed)~* symptomatic primary or metastatic CNS disease.~* Has ongoing vomiting, retching, clinically significant nausea caused by any etiology, or has a history of anticipatory nausea and vomiting.~* Has vomited and/or has had dry heaves/retching within 24 hours prior to the start of cisplatin-based chemotherapy on Day 1 in Cycle 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rolapitant (Type: EXPERIMENTAL): Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV) + dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
- Placebo + Granisetron + Dexamethasone (Type: PLACEBO_COMPARATOR): Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete